Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

AGC and Tenesol create joint venture for custom-made building integrated photovoltaic glass modules

October 11, 2010 5:35 am | by I-Micronews | News | Comments

AGC Glass Europe, a leading glass manufacturer, and Tenesol, a global solar power provider, have created a joint venture for the production of BIPV crystalline SI modules that answer exact customer requirements

austriamicrosystems introduces ?More Than Silicon? initiative

October 11, 2010 5:35 am | by I-Micronews | News | Comments

Foundry customers benefit from compelling package including technology add-ons, services and dedicated support

Mass. medical device firms hit financial stumbling blocks

October 11, 2010 5:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

A trio of public Massachusetts medical device companies – NMT Medical Inc., AdvanSource Biomaterials Corp. and NeuroMetrix Inc. – are struggling to overcome languishing stock prices and dwindling cash as they are hit by scientific and economic setbacks.

Advertisement

ImmunoGen licenses TAP tech to Novartis in $245M+ deal

October 11, 2010 5:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

ImmunoGen Inc. has agreed to work with Novartis on targeted anticancer therapeutics developed using ImmunoGen's Targeted Antibody Payload (TAP) technology, in a deal potentially worth nearly $250 million – and potentially much more.

Express Scripts Accurately Predicts Which Patients Are Likely to Ignore Doctors' Orders

October 11, 2010 5:34 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, Oct. 11 /- Through a set of proprietary computer models, Express Scripts, Inc. (Nasdaq: ESRX ), is now able to accurately predict up to a year in advance which patients are most at risk of falling off their physician-prescribed drug therapy — and to intervene in...

TOPICS:

Arable Corporation Announces New Technology for Clinical Trial Industry

October 11, 2010 5:34 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Oct. 11 /- Arable Corporation ( www.arablecorp.com ) has announced the launch of Arable Perform to bring unique CTMS technologies to the clinical trial industry.  Whereas traditional CTMS systems have been costly and require months to implement, Perform brings CTMS...

TOPICS:

TriReme Medical Announces $17 Million Series D Financing

October 11, 2010 5:34 am | by Bio-Medicine.Org | News | Comments

PLEASANTON, Calif., Oct. 11 /- TriReme Medical, a leading developer of innovative catheters and stents for the treatment of complex vascular disease, announced today the closing of a $17M Round D financing.  The financing was led by Bio*One Capital, a subsidiary of Singapore based...

TOPICS:

Varian Medical Systems and Stanford University Win $3.6 Million Five-Year NIH/NCI Research Grant to Develop Advanced Imaging Technology

October 11, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Oct. 11 /- Scientists from Stanford University and from the Ginzton Technology Center at Varian Medical Systems have jointly received a $3.6 million five-year research grant from the U.S. National Institutes of Health (NIH) to develop advanced imaging technology...

TOPICS:
Advertisement

Chongqing Cancer Hospital Becomes First Hospital in Southwest China to Offer Cancer Patients Fast, Precise Treatment Using RapidArc® Radiotherapy from Varian Medical Systems

October 11, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

BEIJING, and PALO ALTO, Calif., Oct. 11 /- Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while...

TOPICS:

MuGard Provides Significant Improvement or Stabilization of Oral Mucositis in Over 75% of Patients in European Clinical Experience

October 11, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

DALLAS and NEW YORK, Oct. 11 /- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP ), a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's...

TOPICS:

DATATRAK Awarded Three Phase III Studies

October 11, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, Oct. 11 /- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of an Enterprise Agreement for three new Phase III oncology studies with an existing...

TOPICS:

DePuy Orthopaedics Accused of Deceiving Hip Replacement Patients

October 11, 2010 5:32 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, Oct. 11 /- The preeminent law office of Nurenberg, Paris, Heller & McCarthy has filed a class action lawsuit against Johnson & Johnson's artificial joint replacement company DePuy Orthopaedics, Inc., on behalf of clients who suffered damages resulting from the company's...

TOPICS:

IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery

October 11, 2010 5:32 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Oct. 11 /- IRIDEX Corporation (Nasdaq: IRIX ) today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery. The Adjustable & Intuitive Laser...

TOPICS:

Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA

October 11, 2010 5:31 am | by Bio-Medicine.Org | News | Comments

MISSISSAUGA, Ontario, Oct. 11 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) announced today that Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug...

TOPICS:

Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronie's Disease

October 11, 2010 4:31 am | by Bio-Medicine.Org | News | Comments

MALVERN, Pa., Oct. 11 /- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ), a specialty biopharmaceutical company, today announced that the first subject has been dosed in the global phase III program of XIAFLEX® for the treatment of Peyronie's disease.  Peyronie's disease is the...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading